15.9  0 (-4.96%)		04-06 16:00
Open: 15.9 High: 15.9 Volume: 105,554		Pre. Close: 15.9 Low: 15.9 Market Cap: 192(M)

Short term
Mid term
Targets	6-month :	19.48	1-year :	20.18
Resists	First :	16.68	Second :	17.28
Pivot price	16.3
Supports	First :	15.71	Second :	13.07
MAs	MA(5) :	15.89	MA(20) :	16.4
	MA(100) :	16.95	MA(250) :	0
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	12	D(3) :	12
RSI	RSI(14): 33.2
52-week	High :	17.9	Low :	13.17

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SWKH ] has closed above bottom band by 29.9%. Bollinger Bands are 144.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	15.94 - 16.02	16.02 - 16.08
Low:	15.68 - 15.79	15.79 - 15.88
Close:	15.75 - 15.91	15.91 - 16.05

SWK Holdings Corporation (SWKH) operates as a specialized financial institution, primarily concentrating its efforts within the healthcare sector. The company's operations are distinctly divided into two core segments: Finance Receivables and Pharmaceutical Development. Within its finance division, SWK offers bespoke funding solutions tailored to a diverse array of life science enterprises. These include companies spanning biotechnology, medical devices, diagnostic tools, animal health, and pharmaceuticals, alongside various institutions and individual innovators. Furthermore, the company extends non-discretionary investment advisory services, managing separate accounts for institutional clients keen on investing in the life science finance domain. Its Pharmaceutical Development segment involves the creation, formulation, production, and licensing of pharmaceutical products, leveraging its proprietary Peptelligence platform. A key strategic objective here is to license its internally developed product pipeline to external partners, aiming to generate innovative formulations through its unique technology, ultimately designed to benefit patients and their caregivers. Founded in 1996, the company underwent a name change from Kana Software, Inc. to SWK Holdings Corporation in December 2009. Its corporate headquarters are situated in Dallas, Texas.

Sun, 05 Jul 2026
SWKH Q3 2025 Earnings: EPS Surges 70% Above Estimates on Strong Operating Performance - Gross Profit Margin - dars.gov.et

Sat, 13 Jun 2026
SWKH Q3 2025 Earnings: Strong EPS Beat Driven by Favorable Royalty and Financing Income - Profit Inflection Point - dars.gov.et

Sat, 13 Jun 2026
SWKH Q3 2025 Earnings: Strong EPS Beat Driven by Favorable Royalty and Financing Income - Dividend Increase Stocks - dars.gov.et

Fri, 05 Jun 2026
SWKH Q3 2025 Earnings: Strong EPS Beat Drives Investor Confidence - Special Dividend Alert - dars.gov.et

Tue, 07 Apr 2026
Runway Growth Finance Corp. Closes Acquisition of SWK Holdings Corporation and Provides First Quarter 2026 Business and Portfolio Update - Yahoo Finance

Mon, 06 Apr 2026
SWK Holdings completes merger with Runway Growth Finance, delists from Nasdaq - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Financial Services
Industry: Asset Management
Shares Out	12 (M)
Shares Float	2 (M)
Held by Insiders	6.5 (%)
Held by Institutions	86.9 (%)
Shares Short	69 (K)
Shares Short P.Month	95 (K)

EPS	-0.21
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	19.44
Profit Margin	-6.8 %
Operating Margin	19.3 %
Return on Assets (ttm)	-0.9 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	-27.8 %
Gross Profit (p.s.)	2.97
Sales Per Share	3.1
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	27 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-75.72
PEG Ratio	0
Price to Book value	0.81
Price to Sales	5.11
Price to Cash Flow	7.04

Dividend	4
Forward Dividend	0
Dividend Yield	25.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.